Clinical trials: Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer.It's arm to evaluate the neoadjuvant…
- Trial name
- NCT05356351
- Testing
- RC48- ADC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital